Abstract
typhoid conjugate vaccine
WEST
Sodiomon B. Sirima and Matthew B. Laurens Contributed equally to the work.We assessed anti-Vi IgG/IgA responses to typhoid conjugate vaccine (TCV) in children enrolled in a double-blind randomized controlled, phase 2 trial in Burkina Faso. Anti-Vi IgG seroconversion and anti-Vi IgA titers were higher in TCV than control recipients at 30–35 months post-vaccination. TCV induces durable immunity in Burkinabe children vaccinated at 15 months.A single dose of typhoid conjugate vaccine (TCV) induces durable immunity in Burkinabe children vaccinated at 15 months 30–35 months post-vaccination. Extended duration data—of a novel TCV in West Africa—will inform policy and decision-makers considering the country introduction of TCV.